Company news

Dimerix Limited news in 2026

Dimerix Limited's news releases, calls and decks from 2026, newest first.

View company

Dimerix Quarterly Activities Report and Appendix 4C

October 28, 2026

Dimerix Quarterly Activities Report and Appendix 4C

October 28, 2026

New Data Supports Biological Rationale for DMX-200 in FSGS

October 22, 2026

DMX-200 First 100 Patients Complete Phase 3 Trial Treatment

October 15, 2026

First Patient Reaches Four Years in DMX-200 Clinical Program

October 4, 2026

Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility

September 22, 2026

Dimerix DMX-652 Granted Mexican Composition of Matter Patent

September 13, 2026

S&P DJI Announces September 2026 Quarterly Rebalance

September 4, 2026

Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones

September 3, 2026

Dimerix Secures A$34 Million Non-Dilutive Funding Facility

September 3, 2026

Appendix 4E and 2026 Annual Report

August 26, 2026

Dimerix Receives US$10M Upfront Payment from Everest

August 19, 2026

Dimerix Assumes Sponsorship of US IND for New Asset DMX-652

August 16, 2026

Dimerix Presents at Bioshares Summit 2026

August 5, 2026

US Patent Granted for Dimerix New Asset DMX-652

July 22, 2026

Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury

July 17, 2026

Dimerix Expands Pipeline with Acquisition of Phase 2 Asset

July 16, 2026

Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway

July 16, 2026

DMX-200 Available To Patients Via Post-Trial Access Pathways

July 8, 2026

Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines

June 15, 2026

Dimerix Licenses DMX200 to Everest for China and Asia Region

June 15, 2026

Dimerix Quarterly Activities Report and Appendix 4C

April 29, 2026

Blinded assessment of ACTION3 statistical assumptions complete

April 27, 2026

ACTION3 Statistical Review Complete

April 27, 2026

Dimerix to Conduct Review of ACTION3 Statistical Assumptions

March 15, 2026

Dimerix Phase 3 Trial Last Patient Receives First Dose

March 9, 2026

Appendix 4D and Half Year Financial Report

February 25, 2026

Quarterly Appendix 4C and Activities Report

January 28, 2026

Decks in 2026